stephenmascioli

Anika Therapeutics names CMO, COO

pharmafile | April 4, 2016 | Appointment | Sales and Marketing Anika Therapeutics, CMO, COO, Executive appointment 

Anika Therapeutics (Nasdaq: ANIK) on Monday named the executive appointments of Stephen Mascioli the chief medical officer (CMO) and Dana Alexander its chief operations officer (COO).

In the new role Mascioli and Alexander will report to Anika’s chief executive officer, Charles Sherwood.

Sherwood says: “We’re pleased to add Dr Mascioli and Mr Alexander to our executive leadership team as we enter a pivotal phase in Anika’s growth, which is driven by pipeline advancement and global commercial expansion. With Dr Mascioli spearheading the preclinical and clinical development of our robust pipeline and Mr Alexander overseeing and building our manufacturing and operations capabilities, we anticipate tremendous progress in executing our long-term growth strategy.”

Mascioli says: “Anika has an impressive track record in research and development, which has led to a solid and diversified pipeline that spans the continuum from pain management to healing, repair, and regeneration. I’m excited to drive the clinical development strategy, rally the support of key physician thought leaders, and work with our regulatory team to bring Anika’s important therapeutic advances to patients.”

Related Content

ianread

Pfizer CEO Ian Read set to step down from head position

Ian Read is set to step down from his position as Chief Executive Officer (CEO) …

top_10_image

Top Ten most popular articles on Pharmafile.com this week

This week’s pharmaceutical headlines were dominated by legal spats as the state of New York …

shutterstock_38078521

Anika’s osteoarthritis pain drug falls short at Phase 3

Anika Therapeutics has become the latest in a recent string of firms to suffer a …

Latest content